Topiramate
Brand: Topamax (US/EU) / Topamac (IN) / Topamax (BD)
Anticonvulsant
Sodium channel blocker / GABA enhancer / carbonic anhydrase inhibitor
Pharmacokinetics
| Half-life | 21 hours |
| Tmax | 2 h |
| Bioavailability | 80 % (approx) |
| Protein Binding | 15 % |
| Volume of Distribution | 0.6 L/kg (approx) |
| Clearance Route | renal |
| Active Metabolites | no |
| Notes | Causes metabolic acidosis and kidney stones due to carbonic anhydrase inhibition. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
Paresthesia, cognitive slowing, word-finding difficulty, weight loss, kidney stones, metabolic acidosis
Contraindications:
Known hypersensitivity
Precautions:
Monitor bicarbonate; avoid dehydration; caution in patients with renal stones